Aligos Therapeutics Stock Price on November 29, 2024
| ALGS Stock | USD 30.82 3.26 11.83% |
Below is the normalized historical share price chart for Aligos Therapeutics extending back to October 16, 2020. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Aligos Therapeutics stands at 30.82, as last reported on the 11th of December 2024, with the highest price reaching 31.80 and the lowest price hitting 27.10 during the day.
If you're considering investing in Aligos Stock, it is important to understand the factors that can impact its price. Aligos Therapeutics is very risky given 3 months investment horizon. Aligos Therapeutics secures Sharpe Ratio (or Efficiency) of 0.18, which signifies that the company had a 0.18% return per unit of risk over the last 3 months. We were able to analyze and collect data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.64% are justified by taking the suggested risk. Use Aligos Therapeutics Risk Adjusted Performance of 0.0959, downside deviation of 9.45, and Mean Deviation of 5.95 to evaluate company specific risk that cannot be diversified away.
At this time, Aligos Therapeutics' Total Stockholder Equity is comparatively stable compared to the past year. Common Stock Shares Outstanding is likely to gain to about 33.9 M in 2024, whereas Common Stock is likely to drop 4,767 in 2024. . At this time, Aligos Therapeutics' Price Book Value Ratio is comparatively stable compared to the past year. Price To Book Ratio is likely to gain to 4.71 in 2024, whereas Price Earnings Ratio is likely to drop (4.94) in 2024. Aligos Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 16th of October 2020 | 200 Day MA 15.7718 | 50 Day MA 13.8096 | Beta 2.116 |
Aligos |
Sharpe Ratio = 0.1811
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ALGS | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.08 actual daily | 80 80% of assets are less volatile |
Expected Return
| 1.64 actual daily | 32 68% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average Aligos Therapeutics is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aligos Therapeutics by adding it to a well-diversified portfolio.
Price Book 2.2073 | Enterprise Value Ebitda 0.5749 | Price Sales 17.8033 | Shares Float 419.9 K | Wall Street Target Price 103.3333 |
Related Headline
Spero Therapeutics Headline on 29th of November 2024
Acquisition by Aquilo Capital, L.p. of 727 shares of Spero T... by Aquilo Capital, L.p.
Filed transaction by Spero Therapeutics Director . Grant, award or other acquisition pursuant to Rule 16b-3
Aligos Therapeutics Valuation on November 29, 2024
It is possible to determine the worth of Aligos Therapeutics on a given historical date. On November 29, 2024 Aligos was worth 23.43 at the beginning of the trading date compared to the closed value of 25.51. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Aligos Therapeutics stock. Still, in general, we apply an absolute valuation method to find Aligos Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aligos Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Aligos Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 22.61 | 23.70 | 21.51 | 22.99 | 278,654 | |
11/29/2024 | 23.43 | 25.51 | 23.00 | 25.51 | 399,639 |
| 26.28 | 27.89 | 25.06 | 25.72 | 553,184 |
| Backtest Aligos Therapeutics | | | Aligos Therapeutics History | | | Aligos Therapeutics Valuation | Previous | Next |
Aligos Therapeutics Trading Date Momentum on November 29, 2024
| On December 02 2024 Aligos Therapeutics was traded for 25.72 at the closing time. The top price for the day was 27.89 and the lowest listed price was 25.06 . The trading volume for the day was 553.2 K. The trading history from December 2, 2024 was a factor to the next trading day price appreciation. The overall trading delta against the next closing price was 0.82% . The overall trading delta against the current closing price is 12.39% . |
Aligos Therapeutics Fundamentals Correlations and Trends
By evaluating Aligos Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Aligos Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Aligos financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Aligos Therapeutics Stock history
Aligos Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Aligos is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Aligos Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Aligos Therapeutics stock prices may prove useful in developing a viable investing in Aligos Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 24.9 M | 33.9 M | |
| Net Loss | -86.4 M | -90.8 M |
Aligos Therapeutics Quarterly Net Working Capital |
|
Aligos Therapeutics Stock Technical Analysis
Aligos Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Aligos Therapeutics Period Price Range
Low | December 11, 2024
| High |
0.00 | 0.00 |
Aligos Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Aligos Therapeutics December 11, 2024 Market Strength
Market strength indicators help investors to evaluate how Aligos Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Aligos Therapeutics shares will generate the highest return on investment. By undertsting and applying Aligos Therapeutics stock market strength indicators, traders can identify Aligos Therapeutics entry and exit signals to maximize returns
Aligos Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Aligos Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Aligos Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Aligos to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0959 | |||
| Jensen Alpha | 1.21 | |||
| Total Risk Alpha | (0.38) | |||
| Sortino Ratio | 0.1092 | |||
| Treynor Ratio | (1.96) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Aligos Stock Analysis
When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.